Bluestem

What Bluestem does

Bluestem (legally Bluestem API Inc., trading as Bluestem and "SAGE by Bluestem API Inc.") is a privately held Canadian company, incorporated in Ontario and headquartered in Toronto, that operates across three pillars — Research, Technology, and Advocacy — focused on psilocybin-assisted therapy. Its core commercial product is the SAGE platform, a healthcare administrative software platform that uses AI-powered natural language processing (AI Form Filler, Smart Guidance, and One-Click Submit modules) to extract patient information from chart notes and EMRs, pre-populate applications, and digitally submit and track Health Canada Special Access Program (SAP) requests for psilocybin therapy, compressing an hours-long process into minutes. The platform also integrates with EHR systems and secure eFax services, applies AES-256 encryption, and is designed to comply with PIPEDA, PHIPA, and PIIDPA.

The company holds one of only a handful of psilocybin R&D permits issued globally, enabling it to operate regulated psilocybin research alongside its software product. Bluestem's GTM is community-led and product-led, with dedicated programs for Canadian Veterans with Operational Stress Injuries, First Responders, and First Nations, Métis, and Inuit Communities, supplemented by partnerships with advocacy organizations (PsyCan), health authorities (Indigenous communities), supply chain partners (PurMinds NeuroPharma), and policy engagement with Veterans Affairs Canada and Health Canada to expand reimbursement and access.

Commercially, SAGE is currently in beta with free access and monetization strategy not publicly disclosed; the indicated revenue model is recurring subscription for the software platform, alongside professional services around R&D and consulting. The company has 11-50 employees, no disclosed external funding rounds, no parent company, and operates exclusively in Canada with domestic data residency.

Name

Bluestem

Legal name

Bluestem API Inc.

Website

https://bluestem.co

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Bluestem API Inc. is a Toronto-based Canadian company that develops the SAGE AI-powered platform to streamline Health Canada Special Access Program applications for psilocybin-assisted therapy, serving healthcare practitioners and programs for Canadian veterans, first responders, and Indigenous communities.

Ownership category

akta.pro rank

Product category

Healthcare Administrative Software

NAICS

Services for the Elderly and Persons with Disabilities (62412), Services for the Elderly and Persons with Disabilities (624120)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090), Services-Social Services (8300)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industry

Disability Services & Assistive Solutions (Accessibility, Assistive Tech) (BPAGALAM)

Keywords

• Healthcare administration software
• Psilocybin therapy platform
• Clinical workflow automation
• Regulatory submission software
• Psychedelic medicine research

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. SAGE App Platform: Healthcare administrative software and workflow tools for regulated clinical environments. Currently in beta phase with free access; monetization strategy not publicly disclosed.
2. Psilocybin R&D: Research and development operations focused on psilocybin-based treatments under R&D permit.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

SAGE by Bluestem API Inc. is an AI-powered healthcare administrative software platform that auto-populates Health Canada's Special Access Program (SAP) applications for psilocybin-assisted therapy, providing separate portals for healthcare practitioners and patients. Bluestem also conducts psilocybin research and development operations under a Health Canada permit and engages in advocacy partnerships with veterans, first responders, and Indigenous communities.

Product overview

Bluestem operates as a Research, Technology and Advocacy company focused on providing secure software and administrative tools to support regulated clinical and research workflows. The core product is the SAGE platform (SAGE by Bluestem API Inc.), which consists of multiple integrated modules including the AI Form Filler, Smart Guidance, and One-Click Submit features. These modules work together to help healthcare professionals manage documentation, compliance, and operational processes for Health Canada's Special Access Program applications for psilocybin-assisted therapy. The company also holds a psilocybin R&D permit and provides consulting services alongside the software platform.

Differentiator

Problem solved

Functional benefit

Products and services

• SAGE Platform AI-powered healthcare administrative software platform that auto-populates Health Canada's Special Access Program (SAP) applications for psilocybin-assisted therapy, with separate portals for healthcare practitioners and patients.
• Psilocybin Research and Development Services Research and development operations for psilocybin medicines and therapeutic treatments, conducted under a Health Canada permit.
• Consulting Services

Quantifiable outcome

• Reduces SAP application process from hours to minutes
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• PurMinds NeuroPharmacoreStrategic or Co-development PartnerPurMinds NeuroPharma delivered the first botanical psilocybin to Bluestem API Inc., representing a significant supply chain partnership for Bluestem's psilocybin R&D and therapy programs. This partnership supports Bluestem's access to quality-controlled psilocybin products for use in treatment.
• Veterans Affairs CanadacoreOthersBluestem advocates for Veterans Affairs Canada to cover the full costs of psychedelic-assisted therapy for veterans, including SAP consultations, application processes, medicine, and associated therapy. The company works with the department to expand access and reimbursement support.
• First Nations, Métis, and Inuit Health AuthoritiescoreStrategic or Co-development PartnerBluestem works in partnership with Indigenous leaders, healers, practitioners, and patients to co-develop innovative mental health approaches. The company collaborates with local and regional health authorities to secure authorizations and funding, supports capacity-building, and works on research and advocacy.
• PsyCanminorOthersBluestem participates in PsyCan's open letter campaign calling on Veterans Affairs Canada to cover psychedelic-assisted therapy costs for veterans.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cybin: Clinical-stage psychedelic therapeutics company developing psilocybin-based therapies (e.g., CYB003 for MDD). Directly comparable on psychedelic modality, mental health indications, and regulatory pathway.
• GH Research: Clinical-stage company developing psilocybin-based therapies for treatment-resistant depression. Directly comparable to Bluestem on molecule, indication, and regulatory positioning.
• Field Trip Health & Wellness: Operator of psychedelic-assisted therapy clinics and developer of psilocybin programs. Comparable to Bluestem on psychedelic therapy delivery and mental health focus, though focused on clinic operations rather than regulatory/permit-driven models.
• Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Directly comparable to Bluestem on therapeutic modality (psilocybin), indication (TRD), and regulatory pathway, though Compass is publicly listed and focused on registrational trials.
• MindMed: Neuromedicine company developing psychedelic-inspired therapies (including MDMA and LSD programs) for mental health and addiction. Comparable to Bluestem as a psychedelic therapy developer targeting underserved psychiatric indications.

Emerging players

• Clearmind Medicine: Clinical-stage psychedelic pharmaceutical company developing novel psychedelic-derived compounds for mental health and addiction. Comparable emerging player in psychedelic therapeutics.
• Revive Therapeutics: Specialty life sciences company developing psilocybin-based therapeutics (e.g., for methamphetamine use disorder). Comparable emerging player focused on psilocybin drug development.
• Psyence Biomedical: Clinical-stage psychedelic therapy company developing psilocybin-based treatments for mental health and existential distress. Comparable emerging peer on molecule and therapeutic positioning.

Regional players

• Numinus Wellness: Canadian mental health company operating psychedelic-assisted therapy clinics and psilocybin research programs. Strongly comparable to Bluestem on Canadian domicile, psychedelic therapy focus, and regulatory positioning.

Broad incumbents

• ATAI Life Sciences: Clinical-stage biopharmaceutical company building a portfolio of psychedelic and non-psychedelic mental health therapies, including psilocybin. Comparable as a larger, well-capitalized player pursuing similar indications through a broader portfolio approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bluestem_api
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/bluestem-api
• Instagraminstagram.com/bluestem_api

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bluestem